The Rho kinase inhibitor Fasudil up‐regulates astrocytic glutamate transport subsequent to actin remodelling in murine cultured astrocytes
Open accessThe DOI matches its Crossref record; 8 of the 8 references it cites were found in a registry or an index.
Abstract
BACKGROUND AND PURPOSE Glutamate transporters play a major role in maintaining brain homeostasis and the astrocytic transporters, EAAT1 and EAAT2, are functionally dominant. Astrocytic excitatory amino acid transporters (EAATs) play important roles in various neuropathologies wherein astrocytes undergo cytoskeletal changes. Astrocytic plasticity is well documented, but the interface between EAAT function, actin and the astrocytic cytoskeleton is poorly understood. Because Rho kinase (ROCK) is a key determinant of actin polymerization, we investigated the effects of ROCK inhibitors on EAAT activity and astrocytic morphology. EXPERIMENTAL APPROACH The functional activity of glutamate transport was determined in murine cultured astrocytes after exposure to the ROCK inhibitors Fasudil (HA‐1077) and Y27632 using biochemical, molecular and morphological approaches. Cytochemical analyses assessed changes in astrocytic morphology, F‐/G‐actin, and localizations of EAAT1/2. RESULTS Fasudil and Y27632 increased [3 H]‐d‐aspartate (d‐Asp) uptake into astrocytes, and the action of Fasudil was time‐dependent and concentration‐related. The rapid stellation of astrocytes (glial fibrillary acidic protein immunocytochemistry) induced by Fasudil was accompanied by reduced phalloidin staining of F‐actin and increased V max for [3 H]‐d‐Asp uptake. Immunoblotting after biotinylation demonstrated that Fasudil increased the expression of EAAT1 and EAAT2 on the cell surface. Immunocytochemistry indicated that Fasudil induced prominent labelling of astrocytic processes by EAAT1/2. CONCLUSION AND IMPLICATIONS These data show for the first time that ROCK plays a major role in determining the cell surface expression of EAAT1/2, providing new evidence for an association between transporter function and astrocytic phenotype. ROCK inhibitors, via the actin cytoskeleton, effect a consequent elevation of glutamate transporter function – this activity profile may contribute to their beneficial actions in neuropathologies.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Astrocytes: Biology and pathology
Sofroniew, M. V., & Vinters, H. V. (2010) · Acta Neuropathologica · doi:10.1007/s00401-009-0619-8 · Cited by 5,196 · cited 3×
“Glial scar formation is part of the spectrum of adaptive changes in reactive astrogliosis and represents a physical barrier to regenerative events that follow a focal brain injury – in this milieu astrocytes becoming hypertrophic and proliferate (Sofroniew and Vinters, 2010).”
BackgroundInfluentialDanbolt, N. C. (2001) · Progress in Neurobiology · doi:10.1016/s0301-0082(00)00067-8 · Cited by 4,227
Cahoy, J. D., Emery, B., Kaushal, A., Foo, L. C., Zamanian, J. L., Christopherson, K. S., Xing, Y., Lubischer, J. L., Krieg, P. A., Krupenko, S. A., et al. (2008) · The Journal of Neuroscience · doi:10.1523/jneurosci.4178-07.2008 · Cited by 3,129 · cited 2×
“…functions with EAAT2 (~1% of proteome) considered an astrocyte-specific protein like the cytoskeletal marker glial fibrillary acidic protein (GFAP) (Cahoy et al., 2008) – additionally both proteins co-localize and GFAP modulates EAAT function (Hughes et al., 2004; Zhou and Sutherland, 2004; Shobha…”
BackgroundGuide to receptors and channels (GRAC), 5th edition
Alexander, S., Mathie, A., & Peters, J. (2011) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.2011.01649_1.x · Cited by 1,947
ROCKs: multifunctional kinases in cell behaviour
Riento, K., & Ridley, A. J. (2003) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm1128 · Cited by 1,941
β-Lactam antibiotics offer neuroprotection by increasing glutamate transporter expression
Rothstein, J. D., Patel, S., Regan, M. R., Haenggeli, C., Huang, Y. H., Bergles, D. E., Jin, L., Dykes Hoberg, M., Vidensky, S., Chung, D. S., et al. (2005) · Nature · doi:10.1038/nature03180 · Cited by 1,518 · cited 2×
“Increasing evidence indicates that EAATs are subject to at least two broad types of regulation; acutely by rapid trafficking and internalization, and in the longer-term by adaptive mechanisms involving transcriptional induction (Schlag et al., 1998; Duan et al., 1999; Figiel et al., 2003; Fournier et al., 2004; Rothst…”
BackgroundActin Cytoskeleton Regulation in Neuronal Morphogenesis and Structural Plasticity
Luo, L. (2002) · Annual Review of Cell and Developmental Biology · doi:10.1146/annurev.cellbio.18.031802.150501 · Cited by 658 · cited 4×
“The three best-characterized Rho-GTPases are RhoA, Rac and Cdc42, which regulate the depolymerization/polymerization of actin via downstream, interactive signalling cascades (EtienneManneville and Hall, 2002; Luo, 2002; Raftopoulou and Hall, 2004).”
BackgroundInfluentialRegulation of the glial Na+-dependent glutamate transporters by cyclic AMP analogs and neurons.
Schlag, B. D., Vondrasek, J. R., Munir, M., Kalandadze, A., Zelenaia, O. A., Rothstein, J. D., & Robinson, M. B. (1998) · Molecular Pharmacology · doi:10.1124/mol.53.3.355 · Cited by 303
Cited by
ROCK inhibition in models of neurodegeneration and its potential for clinical translation
Koch, J. C., Tatenhorst, L., Roser, A.-E., Saal, K.-A., Tönges, L., & Lingor, P. (2018) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2018.03.008 · Cited by 239
Borrajo, A., Rodriguez-Perez, A. I., Villar-Cheda, B., Guerra, M. J., & Labandeira-Garcia, J. L. (2014) · Neuropharmacology · doi:10.1016/j.neuropharm.2014.05.021 · Cited by 75
Rho Kinase and Dopaminergic Degeneration: A Promising Therapeutic Target for Parkinson’s Disease
Labandeira-Garcia, J. L., Rodríguez-Perez, A. I., Villar-Cheda, B., Borrajo, A., Dominguez-Meijide, A., & Guerra, M. J. (2015) · The Neuroscientist · doi:10.1177/1073858414554954 · Cited by 54
Lau, C. L., Perreau, V. M., Chen, M. J., Cate, H. S., Merlo, D., Cheung, N. S., O'Shea, R. D., & Beart, P. M. (2012) · Journal of Cellular Physiology · doi:10.1002/jcp.22838 · Cited by 49
Self-citation
Metadata
- Authors
- Lau, C., O'Shea, R., Broberg, B., Bischof, L., & Beart, P.
- Venue
- British Journal of Pharmacology
- Publisher
- Wiley
- Published
- 2011-05-11
- Volume
- 163
- Issue
- 3
- Pages
- 533-545
- ISSN
- 0007-1188 (ISSN-L)
- 1476-5381
- OpenAlex
- W1560100279
- Cited by
- 75
- References
- 8
- FWCI
- 2.62
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.